Short answer
MBX Biosciences, Inc. (MBX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
MBX Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results
- Investor focus: quarterly cash position, operating expenses, and pipeline progress in the accompanying release
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation furnished as Exhibit 99.2
- Investor materials available through MBX Biosciences’ website Investors section
- Presentation update may provide refreshed company, pipeline, or strategic information
Item 8.01 · Other Events
- MBX 4291 Phase 1 obesity trial remains on track for first Part C data in Q4 2026
- Part C evaluates a 12-week multiple-ascending-dose regimen in adults with BMI ≥30
- First cohort tests 30 mg weekly for four doses, followed by 120 mg and 180 mg monthly titration
- Q4 readout is a near-term clinical catalyst, but remains subject to development, regulatory, funding, and trial-data risks
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $37.1M versus $19.4M; R&D rose to $31.0M on Phase 3 and obesity-program investment
- $418.6M cash, equivalents and marketable securities; management expects funding into 2029, reducing near-term financing pressure
- Canvuparatide Phase 3 pivotal trial recruiting in Q3 2026 after one-year data showed sustained hypoparathyroidism benefit
- MBX 4291 showed 7% mean weight loss at eight weeks in Phase 1 cohort; 12-week data expected Q4 2026
- New CEO Steve Hoerter and CFO John Smither appointed during transition toward later-stage development and expanded obesity pipeline
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MBX Biosciences, Inc. 8-K filings
Get the next MBX 8-K as it lands
Follow MBX for push alerts, or ask the research agent what this filing means.